Pharma-Bio Serv, Inc. (PBSV) Financial Statements (2025 and earlier)

Company Profile

Business Address INDUSTRIAL ZONE STREET 1
DORADO, 00646
State of Incorp.
Fiscal Year End October 31
Industry (SIC) 8742 - Management Consulting Services (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

1/31/2025
Q1
10/31/2024
Q4
7/31/2024
Q3
4/30/2024
Q2
1/31/2024
Q1
10/31/2023
Q4
7/31/2023
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,9786,3429,9619,4764,53114,584
Cash and cash equivalent      2,870
Short-term investments5,9786,3429,9619,4764,53111,715
Receivables2,5112,5992,6152,4083,9414,631
Other undisclosed current assets7,2106,9943,9386,89110,929515
Total current assets:15,69915,93616,51318,77519,40119,731
Noncurrent Assets
Operating lease, right-of-use asset199239279318356394
Property, plant and equipment1691821263342
Other noncurrent assets226126112112112 
Other undisclosed noncurrent assets      130
Total noncurrent assets:593383412456501566
TOTAL ASSETS:16,29216,31916,92519,23119,90220,297
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,1281,1121,1291,0631,4671,680
Accrued liabilities594625910738534621
Other undisclosed accounts payable and accrued liabilities5334872193259341,059
Debt    1,722  
Other undisclosed current liabilities7607871,069894686770
Total current liabilities:1,8871,8992,1973,6782,1542,450
Noncurrent Liabilities
Liabilities, other than long-term debt 29711131541941,661
Accounts payable and accrued liabilities      1,428
Operating lease, liability 2971113154194233
Other undisclosed noncurrent liabilities6616616611,2431,428 
Total noncurrent liabilities:6907327741,3971,6221,661
Total liabilities:2,5772,6322,9715,0753,7754,111
Equity
Equity, attributable to parent13,71513,68713,95314,15616,12716,185
Common stock222222
Treasury stock, value(548)(548)(546)(544)(537)(536)
Additional paid in capital1,6441,6411,6271,6121,5971,596
Accumulated other comprehensive income262253224225210222
Retained earnings12,35412,33812,64712,86114,85414,901
Total equity:13,71513,68713,95314,15616,12716,185
TOTAL LIABILITIES AND EQUITY:16,29216,31916,92519,23119,90220,297

Income Statement (P&L) ($ in thousands)

1/31/2025
Q1
10/31/2024
Q4
7/31/2024
Q3
4/30/2024
Q2
1/31/2024
Q1
10/31/2023
Q4
7/31/2023
Q3
Revenues2,3332,4182,3782,3803,5984,577
Cost of revenue(1,607)(1,783)(1,759)(1,845)(2,668)(3,027)
Gross profit:7276356185369301,550
Operating expenses(881)(1,017)(932)(974)(982)(1,090)
Operating income (loss):(154)(382)(313)(438)(52)460
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
     (566)127
Income (loss) from continuing operations before equity method investments, income taxes:(154)(382)(313)(438)(618)587
Other undisclosed income from continuing operations before income taxes13992121181570 
Income (loss) from continuing operations before income taxes:(15)(290)(193)(258)(48)587
Income tax expense (benefit)31(19)(21)(13)1(61)
Net income (loss) available to common stockholders, diluted:16(309)(214)(271)(47)526

Comprehensive Income ($ in thousands)

1/31/2025
Q1
10/31/2024
Q4
7/31/2024
Q3
4/30/2024
Q2
1/31/2024
Q1
10/31/2023
Q4
7/31/2023
Q3
Net income (loss):16(309)(214)(271)(47)526
Other comprehensive income (loss)930(2)15(11)(25)
Comprehensive income (loss), net of tax, attributable to parent:25(279)(215)(256)(59)502

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: